Pharmaceutical Swiss drug major Novartis and US peer Bristol-Myers Squibb have announced a clinical collaboration to evaluate the safety, tolerability and preliminary efficacy of three molecularly targeted compounds in combination with B-MS’ investigational PD-1 immune checkpoint inhibitor, Opdivo (nivolumab), in Phase I/II trials of patients with non-small cell lung cancer (NSCLC). 7 October 2014